# Ankit Mahadevia

> Ankit Mahadevia is a Series A investor at Atlas Venture backing Health Care. See 4 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Atlas Venture](https://shizune.co/investors/profile/atlas-venture)
- Location: Cambridge, United States
- Total investments: 4
- Last investment: May 2017
- Lead investor: 25%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/ankit-mahadevia-7988362
- X (Twitter): http://twitter.com/AMahadevia
- Website: https://www.quietleader.com/

Ankit Mahadevia is a Series A investor at Atlas Venture in Cambridge focused on Health Care and Therapeutics. Dr. Ankit Mahadevia is an entrepreneur, physician, author, and advisor focused on building and supporting innovative biotechnology companies. He currently serves as a CXO at Curie Bio, where he works closely with leadership teams on company formation, strategy, financing, and advancement toward human clinical trials.In addition to his operatingrole, Dr. Mahadevia serves as an independent board member and advisor to multiple early- and growth-stage life sciences companies. Since 2023, he has been an advisor and board member at Judo Bio, a company developing novel oligonucleotide therapeutics for kidney disease. He also advises Inductive Bio (New York) and Oath Bio (San Francisco). Over the course of his career, companies he has led, advised, or supported have collectively raised more than $1 billion in financing.Dr. Mahadevia is the author of Quiet Leader Loud Results (Post Hill Press, 2022), which explores how introverted leaders can achieve meaningful organizational impact while leading authentically. He has spoken widely on leadership and innovation, including at the Wharton School, Northwestern University, Harvard University, large pharmaceutical companies, nonprofit organizations, and startups.He is a member of Life Science Cares, a nonprofit organization dedicated to reducing poverty and inequality through engagement with the life sciences industry.Dr. Mahadevia graduated summa cum laude from Northwestern University with a degree in economics and biology. He earned his MD from the Johns Hopkins University School of Medicine and his MBA in healthcare management from the Wharton School of the University of Pennsylvania.

## Contacts

5 contacts available for Ankit Mahadevia: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/ankit-mahadevia?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 25% |
| Therapeutics | 1 | 25% |
| Biotechnology | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series B | 1 | 25% |
| Series C | 1 | 25% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Synlogic | Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. |  | Series C | May 16, 2017 | http://synlogictx.com/ |
| Synlogic | Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | $40M | Series B | Feb 17, 2016 | http://synlogictx.com/ |
| Synlogic | Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. |  | Series A | Oct 07, 2014 | http://synlogictx.com/ |
| Synlogic | Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalentconditions, including inflammatory bowel disease, cancer, and other metabolic conditions. | $29.4M | Series A | Jul 22, 2014 | http://synlogictx.com/ |

4 of 4 investments shown.

## Co-investors
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together
- [Bill & Melinda Gates Foundation](https://shizune.co/investors/profile/bill-melinda-gates-foundation) — VC Fund, 1 deal together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 1 deal together

## About Atlas Venture

VC Fund · Cambridge, United States

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

5 contacts available at Atlas Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Chelsea Place Johnson | Principal | https://shizune.co/investors/profile/chelsea-place-johnson |
| Ed Holson | Entrepreneur-in-Residence | https://shizune.co/investors/profile/ed-holson |
| Jean-Francois Formela | Partner | https://shizune.co/investors/profile/jean-francois-formela |
| Kevin Bitterman | Partner | https://shizune.co/investors/profile/kevin-bitterman |
| Michael Gladstone | Principal | https://shizune.co/investors/profile/michael-gladstone |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ankit Mahadevia invest in?

Ankit Mahadevia invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ankit Mahadevia?

Public channels for Ankit Mahadevia include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Ankit Mahadevia last invest?

The most recent investment recorded for Ankit Mahadevia closed in May 2017. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co